To ensure that scientific research of immediate concern is shared as rapidly as possible, we fast-track accepted articles from the IJTLD and PHA and publish them as edited preprints prior to publication in a journal.
S. Oelofse, A. Esmail, A. H. Diacon F. Conradie, O. Olayanju, N. Ngubane, P. Howell, D. Everitt, A. M. Crook, C. M. Mendel, G. H. Wills, M. Olugbosi, A. del Parigi, E. Sun, A. Calatroni, M. Spigelman, K. Dheda
Article submitted 21 January 2021. Final version accepted 19 February 2021.
There are no data comparing the 6–9 month oral three-drug Nix regimen (bedaquiline, pretomanid and linezolid [BPaL]) to conventional regimens containing bedaquiline (B, BDQ) and linezolid (L, LZD). The authors therefore performed a cohort-comparison study to assess pretomanid in a regimen to treat patients with XDR-TB in Cape Town, South Africa. Patients receiving the BPaL regimen had a significantly better 6-month post-treatment outcome than those on the B–L regimen.